Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine, remifentanil, and labetalol as premedication before ECT
IRCT20141209020258N89Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine, remifentanil and labetalol in Schizophrenia Spectrum Disorders (SSD) (3 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Hemodynamic responses during and after ECT and Seizure duration during ECT. Started Aug 2018; status: completed.
02
Drugs
dexmedetomidineremifentanillabetalol
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on IRCT20141209020258N89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N89.